Inhibrx Biosciences stock gains on insider buying and trial progress

Published on 09/22/2026 at 01:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Inhibrx Biosciences stock has seen notable insider buying through September 16, 2026, as executives commit about USD 4.0 million, according to recent filings. The company also reported encouraging Phase 2 data for INBRX-106 with interim median progression-free survival of 9.6 months.

INBX, US45720L1070, Illustration mit AI erstellt.

Inhibrx Biosciences stock (ISIN US45720L1070) has drawn attention in mid-September 2026 as company insiders committed roughly USD 4.0 million to share purchases through September 16, 2026, while the biotechnology group reports encouraging Phase 2 data for its INBRX-106 antibody in head and neck cancer with an interim median progression-free survival of 9.6 months.

Insider buying supports confidence

According to Xoomar as of September 21, 2026, insiders at Inhibrx Biosciences, Inc. have executed nine trades with a combined value of about USD 4.0 million, involving Chief Executive Officer Mark Lappe and directors Jon Faiz Kayyem and Douglas Forsyth, with the latest transaction dated September 16, 2026.

Detailing that pattern further, an overview from Forecaster shows that on September 16, 2026, director Jon Faiz Kayyem bought 5,000 shares valued at USD 500,000, while earlier on September 8, 2026, Chief Executive Officer Mark Lappe recorded multiple buys including one for 9,681 shares worth about USD 1.09 million, alongside additional purchases between roughly USD 54,000 and USD 664,700.

Clinical data for INBRX-106 provide a fundamental anchor

In parallel with the insider activity, Inhibrx Biosciences continues to emphasize clinical progress in its oncology pipeline. As Newswise reports in a pharmaceuticals research update published around September 21, 2026, the company highlighted that its INBRX-106 candidate in a Phase 2 study for head and neck squamous cell carcinoma achieved an interim median progression-free survival of 9.6 months and nearly doubled the response rate compared with historical benchmarks cited in the study description.

For investors, that combination of a nearly doubled response rate and a median progression-free survival of 9.6 months in the Phase 2 setting provides a concrete efficacy signal that can underpin valuation discussions, particularly when taken together with visible insider buying activity in September 2026.

Stock positioning and investor perspective

The sustained insider purchases through September 16, 2026, amounting to about USD 4.0 million according to Xoomar, signal that key executives and directors are increasing their exposure to Inhibrx Biosciences stock at the same time the company is publicizing favorable Phase 2 data for INBRX-106, which may be interpreted by market participants as a vote of confidence in the longer-term clinical and commercial trajectory.

Stock price and market data

As of the latest available trading data in late September 2026, Inhibrx Biosciences stock trades on Nasdaq in United States dollars; concrete intraday price, prior close, daily percent change, 52-week high and low, market capitalization and volume values for the September 21, 2026 trading session are used by investors to gauge how the shares currently discount the recent insider activity and clinical trial progress.